CL2024000782A1 - Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer - Google Patents
Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimerInfo
- Publication number
- CL2024000782A1 CL2024000782A1 CL2024000782A CL2024000782A CL2024000782A1 CL 2024000782 A1 CL2024000782 A1 CL 2024000782A1 CL 2024000782 A CL2024000782 A CL 2024000782A CL 2024000782 A CL2024000782 A CL 2024000782A CL 2024000782 A1 CL2024000782 A1 CL 2024000782A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- compounds
- thc
- tocopherol
- melatonin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245799P | 2021-09-17 | 2021-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000782A1 true CL2024000782A1 (es) | 2024-09-23 |
Family
ID=83688895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000782A CL2024000782A1 (es) | 2021-09-17 | 2024-03-15 | Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250275935A1 (https=) |
| EP (1) | EP4401717A1 (https=) |
| JP (1) | JP2024535871A (https=) |
| CA (1) | CA3232209A1 (https=) |
| CL (1) | CL2024000782A1 (https=) |
| CO (1) | CO2024004628A2 (https=) |
| PE (1) | PE20241236A1 (https=) |
| WO (1) | WO2023044433A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773527A4 (en) | 2018-03-30 | 2022-04-13 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR44305E (fr) | 1933-12-09 | 1934-12-24 | Meaf Mach En Apparaten Fab Nv | Circuits de voie à rails sans potentiel ou portés au même potentiel |
| US11065225B1 (en) | 2015-07-30 | 2021-07-20 | University Of South Florida | Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease |
| EP3538122B1 (en) * | 2016-11-14 | 2025-03-26 | Farm To Farma, Inc. | Cannabinoid formulations and method of making the same |
| EP3582755A4 (en) * | 2017-02-15 | 2020-12-23 | Molecular Infusions, LLC | PREPARATIONS |
| WO2019036243A1 (en) * | 2017-08-16 | 2019-02-21 | Molecular Infusions, Llc | Formulations |
| US20200246404A1 (en) * | 2017-02-15 | 2020-08-06 | Molecular Infusions, Llc | Formulations |
| EP3773527A4 (en) | 2018-03-30 | 2022-04-13 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES |
| WO2021011421A1 (en) * | 2019-07-12 | 2021-01-21 | University Of South Florida | Compositions and methods for treating alzheimers disease |
-
2022
- 2022-09-16 EP EP22786718.1A patent/EP4401717A1/en active Pending
- 2022-09-16 CA CA3232209A patent/CA3232209A1/en active Pending
- 2022-09-16 US US18/692,705 patent/US20250275935A1/en active Pending
- 2022-09-16 WO PCT/US2022/076579 patent/WO2023044433A1/en not_active Ceased
- 2022-09-16 PE PE2024000480A patent/PE20241236A1/es unknown
- 2022-09-16 JP JP2024517078A patent/JP2024535871A/ja active Pending
-
2024
- 2024-03-15 CL CL2024000782A patent/CL2024000782A1/es unknown
- 2024-04-12 CO CONC2024/0004628A patent/CO2024004628A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023044433A1 (en) | 2023-03-23 |
| PE20241236A1 (es) | 2024-06-19 |
| JP2024535871A (ja) | 2024-10-02 |
| CO2024004628A2 (es) | 2024-05-10 |
| US20250275935A1 (en) | 2025-09-04 |
| CA3232209A1 (en) | 2023-03-23 |
| EP4401717A1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Silibinin prevents autophagic cell death upon oxidative stress in cortical neurons and cerebral ischemia-reperfusion injury | |
| US12465589B2 (en) | Method and composition for treating CNS disorders | |
| Choi et al. | Baicalein protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stress-induced apoptosis through inhibition of reactive oxygen species production and CHOP induction | |
| Attia et al. | Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood | |
| Wang et al. | Inhibition of beta-amyloid-induced neurotoxicity by pinocembrin through Nrf2/HO-1 pathway in SH-SY5Y cells | |
| Yamamoto et al. | Epigallocatechin gallate induces extracellular degradation of amyloid β-protein by increasing neprilysin secretion from astrocytes through activation of ERK and PI3K pathways | |
| Guo et al. | Tangeretin alters neuronal apoptosis and ameliorates the severity of seizures in experimental epilepsy-induced rats by modulating apoptotic protein expressions, regulating matrix metalloproteinases, and activating the PI3K/Akt cell survival pathway | |
| NZ764587A (en) | Use of cannabinoids in the treatment of epilepsy | |
| EP4640275A3 (en) | USE OF CANNABIDIOL IN THE TREATMENT OF ANGELMAN SYNDROME ANXIETY | |
| Tiwari et al. | Synergistic anticancer effects of combined γ-tocotrienol and oridonin treatment is associated with the induction of autophagy | |
| MX2023013338A (es) | Derivados de cannabidiol-c4 para el tratamiento de epilepsia. | |
| Jiang et al. | Inhibition of the integrated stress response reverses oxidative stress damage-induced postoperative cognitive dysfunction | |
| CA2956919C (en) | Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids | |
| Tao et al. | Advances in autophagy modulation of natural products in cervical cancer | |
| CL2024000782A1 (es) | Composiciones y métodos para tratar pacientes con demencia por enfermedad de alzheimer | |
| BR112022021640A2 (pt) | Usos e formulações de canabinoides | |
| GB201120067D0 (en) | Phytocannabinoids for use in the treatment of intestinal inflammatory diseases | |
| Petraglia et al. | Stuck at the bench: Potential natural neuroprotective compounds for concussion | |
| Joseph et al. | Effects of aerobic exercise and dietary flavonoids on cognition: a systematic review and meta-analysis | |
| Nadeem et al. | Exploring the neuroprotective role of asparagus racemosus (Shatavari) in alzheimer’s disease: mechanisms, evidence, and future directions | |
| Dutta | A study from structural insight to the antiamyloidogenic and antioxidant activities of flavonoids: Scaffold for future therapeutics of Alzheimer’s disease | |
| MX2022016038A (es) | Uso de cannabidiol en el tratamiento de la epilepsia. | |
| Fan et al. | LED enhances anti-inflammatory effect of luteolin (3’, 4’, 5, 7-tetrahydroxyflavone) in vitro | |
| Teeravanittrakul et al. | Efficacy of Gingko Biloba Extracted EGb 761® in Treating Primary Tinnitus: A Randomize, Placebo-Controlled, Triple-Blind Clinical Trial. | |
| Kamila et al. | The Role of Lavender Essential Oils (LEO) in Managing Stress and Neuroinflammation: An Immunopsychiatric Perspective |